Arivihan Series A: Funding Correction and Sources

Correction, 4 October 2026: Arivihan, an Indore-based AI tutoring startup, raised US$10 million in a Series A investment co-led by Prosus Ventures and Accel. Prosus confirmed its participation. The financing was reported on 30 September, before this page’s original publication. For the full, sourced account of the same round, read our Arivihan funding report.

What the investment statement supports

Prosus says the money will go toward AI research, Indian-language capabilities, new markets and on-ground distribution. It describes Arivihan as an automated tutoring platform offering interactive lessons, question help and study plans. These are the investor’s descriptions and plans, not independent evidence of improved student results or lower delivery costs.

ETtech independently reported the US$10 million round and interviewed chief executive Ritesh Singh Chandel about plans to expand state-board, CBSE and medical-entrance content. Inc42 and YourStory reported roughly US$200,000 more from GSF-linked angels. That explains why some reports give a US$10.2 million total while the lead investors’ announcement uses US$10 million. These figures refer to one financing event, not two separate rounds.

Why this page was corrected

An earlier version of this page presented specific subscription prices, subscriber counts, referral percentages, internal AI architecture and rollout details without reliable sourcing. Those claims have been removed. The investor announcement itself also uses inconsistent descriptions of the subscriber geography, referring to both “Tier 4” and “Tier 3” cities alongside rural India. Its claim that 80% of subscribers come from those markets should be attributed to the company and investor; it is not an independently audited result.

The key business question remains whether Arivihan can expand across different curricula and languages while maintaining accurate explanations and useful learning outcomes. A funding round does not answer that question. Our original, longer report explains the reported funding amounts, product strategy, source limitations and what future evidence would help families and investors assess the platform.